Gabriel De Leon
Overview
Explore the profile of Gabriel De Leon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
557
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sayour E, Grippin A, De Leon G, Stover B, Rahman M, Karachi A, et al.
Nano Lett
. 2018 Sep;
18(10):6195-6206.
PMID: 30259750
Translation of nanoparticles (NPs) into human clinical trials for patients with refractory cancers has lagged due to unknown biologic reactivities of novel NP designs. To overcome these limitations, simple well-characterized...
2.
Mu L, Long Y, Yang C, Jin L, Tao H, Ge H, et al.
Front Mol Neurosci
. 2018 Apr;
11:82.
PMID: 29643764
Malignant gliomas are heterogeneous brain tumors with the potential for aggressive disease progression, as influenced by suppressive immunoediting. Given the success and enhanced potential of immune-checkpoint inhibitors in immunotherapy, we...
3.
Jin L, Ge H, Long Y, Yang C, Chang Y, Mu L, et al.
Neuro Oncol
. 2017 Jun;
20(1):55-65.
PMID: 28651374
Background: Cancer immunotherapy represents a promising treatment approach for malignant gliomas but is hampered by the limited number of ubiquitously expressed tumor antigens and the profoundly immunosuppressive tumor microenvironment. We...
4.
Sayour E, De Leon G, Pham C, Grippin A, Kemeny H, Chua J, et al.
Oncoimmunology
. 2017 Feb;
6(1):e1256527.
PMID: 28197373
While RNA-pulsed dendritic cell (DC) vaccines have shown promise, the advancement of cellular therapeutics is fraught with developmental challenges. To circumvent the challenges of cellular immunotherapeutics, we developed clinically translatable...
5.
Hoang-Minh L, Deleyrolle L, Siebzehnrubl D, Ugartemendia G, Futch H, Griffith B, et al.
Oncotarget
. 2016 Jan;
7(6):7029-43.
PMID: 26760767
KIF3A, a component of the kinesin-2 motor, is necessary for the progression of diverse tumor types. This is partly due to its role in regulating ciliogenesis and cell responsiveness to...
6.
Sayour E, McLendon P, McLendon R, De Leon G, Reynolds R, Kresak J, et al.
Cancer Immunol Immunother
. 2015 Jan;
64(4):419-27.
PMID: 25555571
Glioblastoma multiforme (GBM) is an aggressive malignancy associated with profound host immunosuppression mediated in part by FoxP3 expressing regulatory CD4+ T lymphocytes (Tregs) that down-regulate anti-tumor immunity. In order to...
7.
Miao H, Choi B, Suryadevara C, Sanchez-Perez L, Yang S, De Leon G, et al.
PLoS One
. 2014 Apr;
9(4):e94281.
PMID: 24722266
Glioblastoma (GBM) is the most common primary malignant brain tumor in adults and is uniformly lethal. T-cell-based immunotherapy offers a promising platform for treatment given its potential to specifically target...
8.
Nair S, De Leon G, Boczkowski D, Schmittling R, Xie W, Staats J, et al.
Clin Cancer Res
. 2014 Mar;
20(10):2684-94.
PMID: 24658154
Purpose: Despite aggressive conventional therapy, glioblastoma (GBM) remains uniformly lethal. Immunotherapy, in which the immune system is harnessed to specifically attack malignant cells, offers a treatment option with less toxicity....
9.
Ajay D, Sanchez-Perez L, Choi B, De Leon G, Sampson J
Curr Drug Discov Technol
. 2012 Feb;
9(4):237-55.
PMID: 22339070
With an average life expectancy of 14 months, Glioblastoma multiforme (GBM), is the most aggressive primary brain tumor. Our growing understanding of the immune system and its role in oncogenesis...
10.
De Leon G, Mitchell D, Sampson J
Future Oncol
. 2011 Mar;
7(3):331-4.
PMID: 21417898
No abstract available.